Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2022
2021
2020
Profitability Metrics
Gross Margin
100.00%
Operating Margin
88.22%
Net Margin
89.38%
Efficiency Metrics
Revenue per Expense Ratio
8.53
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
18.05%
Income Tax Rate
0.00%
EPS
0.8400000000
Balance Sheet Analysis
Current Ratio
0.10
Cash Ratio
0.04
Working Capital
$-71.96M
Debt to Equity
0.54
Debt to Assets
33.67%
Equity Ratio
62.61%
Cash Flow Analysis
Operating Cash Flow Ratio
71.52%
Free Cash Flow Ratio
71.52%
CapEx to Revenue
0.00%
Dividends Paid
$18.27M
Stock Buybacks
No buybacks
Total Shareholder Returns
$18.27M
Cash Position Change
753.94%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
280.10%
Net Income
252.51%
EPS
250.00%
Operating Income
-2.55%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-27.14%
Operating Cash Flow
-78.40%
Free Cash Flow
-78.40%
Balance Sheet Health
Assets
8.05%
Debt
14.36%
Book Value per Share
-0.92%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
-1.00%
Shares Outstanding
1.50%
Long Term Trends
3Y Revenue/Share
-64.85%
5Y Revenue/Share
37.06%
3Y Dividend/Share
-32.76%
5Y Dividend/Share
7.04%